The China Hemostats Market was valued at $47.4 Million in 2025 and projected to reach to $77.2 Million by 2030, representing a compound annual growth rate of 10.3%. China's hemostats market is positioned for sustained growth through 2030, with the market expanding from $47.4 million in 2025 to $77.2 million by 2030.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China's hemostats market is growing at 10.3% CAGR, significantly outpacing the global rate of 6.4%, driven by modernization of surgical facilities and increased healthcare investment across tier-2 and tier-3 cities.
Rising surgical procedures in China, including orthopedic, cardiovascular, and trauma surgeries, are creating sustained demand for advanced hemostatic solutions in both public hospitals and private surgical centers.
Chinese hospitals are increasingly adopting advanced hemostatic technologies including topical agents, mechanical devices, and combination products, replacing traditional methods and improving surgical outcomes.
Government healthcare reforms and rising disposable incomes are driving increased spending on surgical supplies and advanced medical devices, creating favorable market conditions for premium hemostat products.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | RECONSTRUCTIVE SURGERY (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 6.4% from 2025 to 2030 |
| Largest Segment | HOSPITALS (End User) |
| Market Size Base Year (Billions) | ~USD 2.93 (2025) |
| Revenue Forecast (Billions) | ~USD 4 (2030) |
| Segments Covered | Type, Formulation, Application, End User |
4 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 98.1 | 107.7 | 118.5 | 130.4 | 143.8 | 158.7 | 175.5 | 194.3 | 10.4 |
| OTHERS | 15.2 | 16.2 | 17.4 | 18.7 | 20 | 21.5 | 23.2 | 25 | 7.5 |
| SPECIALTY CLINICS | 30.5 | 33.1 | 36 | 39.2 | 42.8 | 46.7 | 51.1 | 55.9 | 9.2 |
| TOTAL | 143.8 | 157.1 | 171.9 | 188.3 | 206.6 | 226.9 | 249.7 | 275.2 | 9.9 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CSL LIMITED | United States | Public Company | Thrombin Hemostats,Combination Hemostats,Gelatin Hemostats, |
| BAXTER | United States | Public Company | Thrombin Hemostats,Combination Hemostats,Gelatin Hemostats, |
| PFIZER INC. | United States | Public Company | Thrombin Hemostats,Combination Hemostats,Gelatin Hemostats, |
| BECTON, DICKINSON AND COMPANY (BD) | United States | ||
| TELEFLEX INCORPORATED | United States | Public Company | Thrombin Hemostats,Combination Hemostats,Gelatin Hemostats, |
| MEDTRONIC PLC | Ireland | Public Company | Thrombin Hemostats,Combination Hemostats,Gelatin Hemostats, |
| STRYKER | United States | Public Company | Thrombin Hemostats,Combination Hemostats,Gelatin Hemostats, |
| INTEGRA LIFESCIENCES | United States | Public Company | Thrombin Hemostats,Combination Hemostats,Gelatin Hemostats, |
| ADVANCED MEDICAL SOLUTIONS GROUP PLC | United Kingdom | Public Company | Gelatin-based hemostats,Collagen-based hemostats,Combination hemostats and biosurgical adjuncts, |
| SAMYANG CORPORATION | Korea, Republic of | Public Company | Thrombin Hemostats,Combination Hemostats,Gelatin Hemostats, |
CSL LIMITED is a public company founded in 1916 and headquartered in the United States, employing 29,904 people. The company operates in the biotechnology and pharmaceutical sectors.
BAXTER is a public company founded in 1931 in the United States, employing 37,500 people. The company operates in the medical devices and pharmaceutical sectors.
PFIZER INC. is a public company founded in 1950 in the United States with 1,244 employees. The company operates in the pharmaceutical and healthcare industry.
BECTON, DICKINSON AND COMPANY (BD) is a company headquartered in the United States. The company operates in the medical devices and healthcare sectors.
TELEFLEX INCORPORATED is a public company founded in 1943 in the United States, employing 15,500 people. The company manufactures medical devices and specialty healthcare products.
MEDTRONIC PLC is a public company founded in 1949 and headquartered in Ireland, employing 95,000 people. The company is a global leader in medical technology and healthcare solutions.
STRYKER is a public company founded in 1941 in the United States, employing 56,000 people. The company is a leading manufacturer of medical devices and surgical equipment.
INTEGRA LIFESCIENCES is a public company founded in 1989 in the United States, employing 4,427 people. The company develops and manufactures medical devices and regenerative medicine products.
ADVANCED MEDICAL SOLUTIONS GROUP PLC is a public company founded in 1991 in the United Kingdom, employing 1,800 people. The company specializes in advanced wound care and medical device solutions.
SAMYANG CORPORATION is a public company founded in 1961 in the Republic of Korea, employing 1,994 people. The company operates in the chemical and pharmaceutical manufacturing sectors.
China's hemostats market is estimated at $47.4 million in 2025, with verified data confirming strong market fundamentals and growth potential.
China's hemostats market is forecasted to reach $77.2 million by 2030, representing a 10.3% compound annual growth rate over the five-year period.
China's 10.3% CAGR significantly outpaces the global hemostats market CAGR of 6.4%, making China one of the fastest-growing regional markets.
Key drivers include increasing surgical volumes, government healthcare reforms, hospital modernization investments, aging population demographics, and rising adoption of minimally invasive procedures in China.
China's rapid market expansion, large patient population, and substantial healthcare infrastructure investments position it as a critical growth engine for the broader Asia Pacific hemostats sector.
The study analyzes key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, as well as the competitive landscape of the hemostats market, to analyze market players on various parameters within the broad categories of business and product strategy. Top-down approach was used to estimate the market size. The market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
The secondary research process involved extensive use of various secondary sources, including directory databases like Bloomberg Business, Factiva, and D&B Hoovers, white papers, annual reports, company house documents, investor presentations, and SEC filings. This research was conducted to gather information valuable for a comprehensive, technical, market-oriented, and commercial study of the hemostats market. It also helped obtain critical insights about key players in the industry, market classification, and segmentation based on current industry trends down to the finest details. Additionally, a database of leading industry players was created through this secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
A breakdown of the primary respondents for the hemostats market is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Others include sales, marketing, and product managers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
The research methodology used to estimate the size of the hemostats market includes the following details.
The market sizing was undertaken from the global side.
Top-down was used to estimate and validate the hemostats market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
During surgical procedures, damage to blood vessels necessitates immediate intervention to mitigate hemorrhage—this process is referred to as hemostasis. Hemostatic agents work by facilitating the formation of fibrin clots, providing an interim solution to manage bleeding at the site. The application of hemostatic measures must be executed rapidly, precisely localized, and meticulously regulated, particularly in scenarios involving significant blood loss or in patients with congenital coagulopathies or trauma-induced vascular compromise.
Full forecast, segment splits, and company analysis for all Hemostats Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report